Cosmos Health Inc COSM

By Brad Sorensen, CFA NASDAQ: COSM READ THE FULL COSM RESEARCH REPORT Cosmos Health (NASDAQ: COSM) has spent the past several years building what management describes as a vertically integrated healthcare platform spanning pharmaceutical manufacturing, distribution, proprietary brands, nutraceuticals, R&D, and telehealth. Two announcements released on September 28 and September 29 provide

* Record Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarm * Revenue up 4.3x under Cosmos Health ownership \- from ~$14 million in fiscal 2017, the last full year before acquisition, to an annualized run-rate of over $60 million; ~330% growth at a CAGR of approximately 18% * Successive record revenue years in 2023, 2024 and 2025, with 2026 expected to continue the trend, based on distribution volumes and performance to date * Ph

* Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreements * Gross margins of over 90% \- among the highest-margin revenue streams in the Company, with raw materials largely supplied by clients * Record production pipeline of more than 32.7 million units, up approximately sixfold since mid-2024 and close to threefold since the start of this year, with

7 million contracted units added in under two weeks \- Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today * Secured orders for 1.

* Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock * Positions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing tokenized IP-backed assets. * CCX0722 is an ingestible, hydrogel-based medical device in development for weight management, using a mechanical mechanism with no systemic absorption * Intellectual property owned outright, with pat

* 500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories * Expands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing portfolio * Cumulative contract manufacturing orderbook increases to more than 27.

By Brad Sorensen, CFA NASDAQ: COSM READ THE FULL COSM RESEARCH REPORT We view Cosmos Health’s (NASDAQ: COSM) latest launch of C-ScrubVet as an intriguing extension of the company’s strategy of using its existing manufacturing, regulatory, distribution, and brand infrastructure to enter additional healthcare markets without having to build an entirely new business from scratch. The veterinary

2 million in adjusted EBITDA and $31 million in net incomeCHICAGO, IL / ACCESS Newswire / September 9, 2026 / ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has received its first orders for its veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet.C-ScrubVet Wash 4% CHDG is a veterinary antimicrobial cleanser containing 4% chlorhexidine digluconate, effective against bacteria

$8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilutionSimplified capital structure, with no effective shelf registration statement or ATM program, and no structured warrants or variable interest rate instruments without a floorOperating cash requirements reduced by more than 30%, reflecting revenue growth, operating efficiencies, improved operating leverage and cost control

CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting Oliv18™ to generate over $6 million in incremental annual U.S. revenue within the next 12 to 18 months, representing approximately $4.3 million in gross profit at an expected gross margin of approximately 72%. Oliv18™ is part of the Company's "18 Series," a growing portfolio of science-based

Innova is backed by leading investors and healthcare groups: Alkhabeer Capital, with more than $2.5 billion AUM; Tamer Group, a pharma manufacturing partner to Astellas and Daiichi Sankyo; and Cigalah Group, whose healthcare arm reports sales exceeding $2 billionInitial purchase order of 126,000 Sky Premium Life units secured on execution of the agreementExclusive rights across Saudi Arabia for an initial five years, spanning pharmacies, retail and online platforms, with potential to renew for a

Highest Q2 and H1 revenue in Company history, reflecting strength across all core segments and reaching a new milestone with an adjusted annualized revenue run-rate exceeding $75 millionContinued progress toward profitability targets, with adjusted gross profit reaching approximately $7.4 million on an annualized basis, adjusted gross margin expanding 165 basis points to 9.54%, and adjusted EBITDA improving 13.8%Demonstrated operating leverage and disciplined inventory management, with Q2 operat

By Brad Sorensen, CFA NASDAQ: COSM READ THE FULL COSM RESEARCH REPORT Cosmos Health (NASDAQ: COSM) delivered a strong second-quarter update that, in our view, provides additional evidence that the company is transitioning from a collection of healthcare assets into a larger, vertically integrated healthcare platform with increasingly meaningful scale. The headline numbers were encouraging: record

Digital subscription platform brings together the Company’s proprietary consumer health products across consumer (B2C) and corporate (B2B) channelsCustomers can begin through one of three paths: a free nutritionist consultation, an AI-powered assistant, or building their own packageCorporate offering supports employee wellness programs and corporate gifting through multi-recipient management, tiered volume pricing, centralized billing, and dedicated account managementFuture platform enhancements

By Brad Sorensen, CFA NASDAQ: COSM READ THE FULL COSM RESEARCH REPORT Cosmos Health (NASDAQ: COSM) has continued to strengthen its position as a diversified, vertically integrated global healthcare company with operations spanning pharmaceutical manufacturing, nutraceuticals, over-the-counter healthcare products, pharmaceutical distribution, telehealth, and artificial intelligence-driven drug

Cosmos Health expands its Sky Premium Life partnership with Pharma Cell in Albania, with average monthly orders already exceeding 4,500 units, and projected to exceed 54,000 annually Products are distributed across Albania and recommended by doctors and healthcare professionals, supporting broad consumer accessExpansion builds on the partnership launched in April 2025 and reflects Sky Premium Life's continued global growth CHICAGO, July 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos He

CHICAGO, July 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 274,000 shares of its common stock in the open market at an average price of approximately $0.2554 per share. The Company has now repurchased a total of 5,112,000 shares for approximately $1.11 million under its previously announced share repurchase program of up to $5 mi